PRINCETON, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer Mojdeh Poul and chief financial officer Lea Knight will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 2:15 p.m ET or 11:15 a.m PT A live webcast of the presentation will be available on the Integra LifeSciences investor relations website under EVENTS & PRESENTATIO ...

Headshot for Oliver Engert Oliver Engert, Chief Administrative Officer, Enovis Dallas, TX, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology company, has announced that Oliver Engert has been appointed Chief Administrative Officer, effective today. In this newly-created role, Oliver will be responsible for leading Enovis’ strategy development, driving organizational efficiency and enhancing operational excellence to support the company in its nex ...

MOUNTAIN VIEW, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in artificial intelligence (AI) technology for coronary artery disease (CAD), today announced that members of management will present at the upcoming 44th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, January 13, 2026, at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived version of the presentation will be available on the Investor Relations section of the H ...

SAN JOSE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that Chair & CEO Leslie Trigg will present at the 44th annual J.P. Morgan Healthcare conference on Wednesday, January 14, 2026, at 4:30 p.m. Pacific time. A live and archived webcast of the presentation will be available on the “Investors” section of the Outset website at https:/ ...

Core Insights - AVITA Medical, Inc. has appointed Joe Woody as a new non-executive Director, while Lou Panaccio has retired after serving as Chairman for over a decade [1][7] Company Leadership Changes - Joe Woody brings over two decades of leadership experience in the medical technology sector, having previously served as CEO of Avanos Medical and President and CEO of Acelity Holdings [2] - Lou Panaccio has been recognized for his significant contributions to the company's commercial and operational strategy during his tenure [2][3] Company Overview - AVITA Medical specializes in therapeutic acute wound care, focusing on innovative solutions that optimize wound healing and accelerate patient recovery [4] - The company's flagship product, the RECELL System, is FDA-approved for treating thermal burn and trauma wounds, utilizing a patient's own skin to create Spray-On Skin™ Cells [4] - In addition to RECELL, AVITA holds exclusive rights to market and distribute PermeaDerm and Cohealyx, both of which are advanced wound care products [4] International Market Presence - The RECELL System is also approved in international markets for a variety of applications, including thermal burn and trauma wounds, with regulatory clearances in Europe, Australia, and Japan [5]

MESA, ARIZONA / ACCESS Newswire / January 5, 2026 / Medical Care Technologies Inc. (OTC Pink:MDCE) announced today that the Company has successfully completed its internal readiness testing phase for its forthcoming AI-powered mobile application designed for skin lesion pre-screening and risk-awareness. The mobile application is scheduled for public release later this year. ...

Core Viewpoint - Lantheus Holdings has successfully completed the sale of its single photon emission computed tomography (SPECT) business to SHINE Technologies, allowing the company to concentrate on its PET radiodiagnostics and microbubbles portfolio while advancing its pipeline of radiopharmaceuticals [1] Group 1 - Lantheus has divested its SPECT business, which includes diagnostic agents and manufacturing operations located in North Billerica, Massachusetts, as well as related operations in Canada [1] - The divestiture aligns with Lantheus' strategy to focus on its growing commercial portfolio and enhance its research and development efforts in radiopharmaceuticals [1]

Group 1 - The firm Stephens raised the price target on Glaukos (GKOS) to $145 from $115 and maintains an Overweight rating on the shares [1] - The outlook for non-iDose U.S. glaucoma revenue was slightly moderated, while iDose revenue expectations were modestly increased [1] - Glaukos is viewed as "one of the best multi-year medtech growth stories" entering 2026, driven by expanding reimbursement, deeper utilization, a growing surgeon base, and a long runway of untreated and uncontrolled glaucoma patients [1]

Core Insights - Intelligent Bio Solutions (INBS) has announced a strategic manufacturing partnership with Syrma Johari MedTech Ltd to enhance global production capabilities and long-term profitability [1][7][8] - The partnership aims to build a more resilient supply chain and improve margins ahead of INBS's planned entry into the U.S. market [2][4] Company Developments - INBS's shares surged 132.4% to close at $9.53 following the announcement, although the stock has seen a 47.9% decline over the past six months compared to a 7.1% growth in the industry [3] - The partnership is expected to yield over 40% in annual production cost savings and a 20-point improvement in gross margins [9][10] - Syrma Johari will significantly expand INBS's manufacturing capacity, providing approximately four times its current capacity [9][10] Operational Benefits - The collaboration is anticipated to lower production costs, enhance gross margins, and mitigate supply-chain risks through diversified manufacturing [4][9] - Syrma Johari operates 14 manufacturing facilities and four design centers across multiple regions, which will support INBS's broader commercial expansion [10] Industry Outlook - The global drug screening market is projected to grow from $9.1 billion in 2024 to $19.5 billion by 2029, with a CAGR of 16.6%, driven by increased drug and alcohol consumption and stricter testing regulations [11]

Core Insights - Baxter International Inc. is considered one of the top cheap stocks under $20, with a current price target of $19.00 set by Wells Fargo analyst Larry Biegelsen, who maintains a Hold rating on the stock [1] - Recent data from a collaboration with The University of Texas Medical Branch indicates that the integration of smart infusion pumps with hospital electronic medical records has positively impacted clinician productivity, patient safety, and programming compliance [1][2] - Morgan Stanley analyst Patrick Wood has reduced the price target for Baxter to $15 from $19 while maintaining an Underweight rating, citing a solid industry setup for MedTech going into 2026 [3] Company Overview - Baxter International Inc. offers a diverse portfolio of essential healthcare products, including parenteral nutrition therapies, dialysis therapies, inhaled anesthetics, generic injectable pharmaceuticals, sterile IV solutions, infusion systems, surgical products, patient monitoring technologies, and respiratory health devices [4] - The company's operations are segmented into regions: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom [4] Market Position - The findings from the smart pump EMR integration study suggest a reduction in patient safety alerts and programming time, highlighting the potential of connected infusion therapy to enhance patient safety and alleviate clinician burnout [2] - Analysts believe that the MedTech sector is well-positioned for growth, supported by major product cycles and favorable hospital spending environments [3]